CRVO logo

CERVOMED INC

CRVONASDAQ
🏆 #4436 by market capEarnings Nov 16US Equity
——
Quote unavailable
🔔
Track CRVO
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$34M
Small Cap
📈Revenue Growth (YoY)
-94.3%
Declining
📊Gross Margin
-230.4%
Thin
💵FCF Margin
—
⚖️P/S Ratio
16.1x
Expensive
Otter Score
—
Insufficient data
No chart data available for CRVO.

Trading Snapshot

Day Range
—
52-Week Range
$2.13 – $10.00
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
15.1M
Next Earnings
2026-11-16

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
16.1x
EPS (TTM)
$-3.21
Dividend Yield
—
Dilution (1yr)
+6.3%
CRVO logo

CERVOMED INC

CRVO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$28M▲ +55.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$23M▲ +41.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.3M▲ +6.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▼ −$764K YoY
StockOtter · stockotter.space

About CERVOMED INC

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.